Uric acid: functions and determination
Safety: what we know, what we dont What clinical trial safety reviews suggest The clinical safety review literature reports several reassuring signals: No meaningful increase in IGF-1 in monitored long-term studies (jofem.org) No clear negative effect on carbohydrate metabolism in testing described (contrast with full hGH) (jofem.org) No clear immunogenicity signal (e.g., anti-AOD antibodies) in the subset assessed in those trials (jofem.org) The major limitation: long-term real-world certainty is thin The problem with many peptides is not that everything is dangerousits that the certainty level is often lower than patients assume
It requires the largest injection volumes, which means you may need a larger syringe for higher doses
[DOI] [PubMed] [Google Scholar] 105.Martins I.L., Charneira C., Gandin V., Ferreira da Silva J.L., Justino G.C., Telo J.P., Vieira A.J., Marzano C., Antunes A.M
TSH is released from the anterior pituitary in response to thyrotropin-releasing hormone (TRH) from the hypothalamus
